Geode Capital Management LLC Boosts Position in BioScrip, Inc. (BIOS)
Geode Capital Management LLC raised its stake in shares of BioScrip, Inc. (NASDAQ:BIOS) by 15.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 944,054 shares of the company’s stock after buying an additional 125,098 shares during the period. Geode Capital Management LLC owned 0.78% of BioScrip worth $1,604,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of BioScrip during the first quarter valued at approximately $7,422,000. Teachers Advisors LLC boosted its position in shares of BioScrip by 14.0% in the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock valued at $169,000 after buying an additional 20,000 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of BioScrip by 1.1% in the first quarter. Wells Fargo & Company MN now owns 113,710 shares of the company’s stock valued at $193,000 after buying an additional 1,254 shares during the last quarter. State Street Corp boosted its position in shares of BioScrip by 10.6% in the fourth quarter. State Street Corp now owns 1,456,697 shares of the company’s stock valued at $1,515,000 after buying an additional 139,110 shares during the last quarter. Finally, American International Group Inc. boosted its position in shares of BioScrip by 73.8% in the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock valued at $115,000 after buying an additional 28,787 shares during the last quarter. Institutional investors own 84.15% of the company’s stock.
BioScrip, Inc. (BIOS) traded down 0.33% during mid-day trading on Friday, hitting $3.02. 220,118 shares of the stock were exchanged. The firm has a 50-day moving average price of $2.91 and a 200-day moving average price of $2.17. BioScrip, Inc. has a 12-month low of $0.98 and a 12-month high of $3.43. The stock’s market capitalization is $384.97 million.
BioScrip (NASDAQ:BIOS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The firm had revenue of $218.11 million during the quarter, compared to the consensus estimate of $220.05 million. The company’s revenue for the quarter was down 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.14) EPS. Equities analysts predict that BioScrip, Inc. will post ($0.55) earnings per share for the current fiscal year.
BIOS has been the subject of several recent analyst reports. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a report on Wednesday, May 10th. Jefferies Group LLC reiterated a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. ValuEngine cut shares of BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. BidaskClub cut shares of BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Finally, SunTrust Banks, Inc. upgraded shares of BioScrip from a “hold” rating to a “buy” rating and raised their target price for the stock from $3.25 to $3.75 in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. BioScrip currently has an average rating of “Hold” and an average price target of $3.75.
In related news, Director Coliseum Capital Management, L sold 886,478 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is currently owned by insiders.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.